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Aims To validate a model for quantifying the prognosis of patients with pulmonary embolism (PE). The
model was previously derived from 10 534 US patients.
Methods and results We validated the model in 367 patients prospectively diagnosed with PE at 117
European emergency departments. We used baseline data for the model’s 11 prognostic variables to
stratify patients into ﬁve risk classes (I–V). We compared 90-day mortality within each risk class and
the area under the receiver operating characteristic curve between the validation and the original deri-
vation samples. We also assessed the rate of recurrent venous thrombo-embolism and major bleeding
within each risk class. Mortality was 0% in Risk Class I, 1.0% in Class II, 3.1% in Class III, 10.4% in Class
IV, and 24.4% in Class V and did not differ between the validation and the original derivation
samples. The area under the curve was larger in the validation sample (0.87 vs. 0.78, P ¼ 0.01). No
patients in Classes I and II developed recurrent thrombo-embolism or major bleeding.
Conclusion The model accurately stratiﬁes patients with PE into categories of increasing risk of mor-
tality and other relevant complications. Patients in Risk Classes I and II are at low risk of adverse out-
comes and are potential candidates for outpatient treatment.
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Introduction
The mortality of acute pulmonary embolism (PE) varies
widely, ranging from .95% in patients who experience car-
diorespiratory arrest to ,2% in patients with a non-
massive embolus.1–3 A risk stratiﬁcation tool that accurately
quantiﬁes the prognosis of patients with PE may be useful in
guiding the intensity of initial treatment. For example,
patients estimated to be at low risk could be discharged
early or managed entirely as outpatients using low-
molecular-weight heparin,4 whereas patients estimated at
high risk may beneﬁt from a more intensive surveillance.
We previously developed a clinical prognostic model that
accurately stratiﬁes patients into ﬁve severity classes of
increasing risk of 30-day mortality and other adverse
medical outcomes such as non-fatal recurrent venous
thrombo-embolism (VTE) and major bleeding.5 The model
comprised 11 routinely available clinical parameters and
provides physicians a beside risk assessment tool for patients
with PE, without any need for imaging studies such as echo-
cardiography or laboratory tests.5
Geographic and follow-up period transportabilities are
important components of the generalizability of a prognos-
tic model.6 These components require that the model’s pre-
dictions remain reliable and accurately discriminate key
outcomes when re-tested in patients from other locations,
using different periods of follow-up.6 To assess these dimen-
sions of generalizability, we validated our prognostic model
in a multicentre study of PE conducted in France and
Belgium using a follow-up period of 90 days.7
Methods
Initial derivation of the prognostic model
Using administrative and clinical data from the Pennsylvania Health
Care Cost Containment Council and the MediQual Atlas databases,
we derived the original prognostic model from 10 534 adult
patient discharges from 186 Pennsylvania hospitals with an ICD-9-
CM diagnosis of PE.5 To derive our rule, we used patient demo-
graphics (age and sex), comorbid conditions (cancer, heart failure,
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ischaemic heart disease, chronic lung disease, chronic renal disease,
cerebrovascular disease, severe neurological disease, and smoking
status), and physical examination ﬁndings (body temperature,
pulse, systolic blood pressure, respiratory rate, mental status, and
arterial oxygen saturation). All of these predictor variables were
recorded at the time of patient presentation and were previously
shown to be associated with short-term mortality in patients with
PE or other acute diseases.8–15
The primary study outcome was death from all causes within 30
days of hospitalization, and this outcome was ascertained using
data from the US National Death Index.16 The original prediction
rule consisted of 11 predictors of mortality (Table 1): two demo-
graphic variables (age and male sex), three comorbid conditions
(cancer, heart failure, and chronic lung disease), and six clinical
factors (temperature ,368C, pulse 110 per minute, systolic
blood pressure ,100 mmHg, respiratory rate 30 per minute,
altered mental status, and arterial oxygen saturation ,90%).5
Each predictor variable was assigned an integer score directly pro-
portional to the magnitude of its beta-coefﬁcient derived from a
logistic regression model of mortality. We computed a prognostic
score for each patient by adding their age in years and the assigned
points for each of the predictor variables documented for that
patient. We partitioned the full range of risk scores into quintiles,
with each quintile representing a prognostic risk class for 30-day
mortality (Class I, very low risk; Class II, low risk; Class III, inter-
mediate risk; Class IV, high risk; and Class V, very high risk)
(Table 1).5 In the original derivation sample, the 30-day overall mor-
tality was 9.2% and the risk-class-speciﬁc mortality varied from 1.1%
in Risk Class I to 24.5% in Risk Class V.5 Detailed information concern-
ing the derivation process and results were published elsewhere.5
Validation sample
We externally validated our model in a cohort of patients prospec-
tively identiﬁed to assess the appropriateness of diagnostic testing
for patients with suspected PE.7 These patients were enrolled in
emergency departments at 117 teaching (n ¼ 23) and non-teaching
(n ¼ 94) hospitals in France and Belgium between 13 January 2003
and 16 February 2003. Patients were excluded from this study if
the diagnosis of PE was documented before the time of presentation
or was made after a hospital stay of .2 days, or if diagnostic testing
for PE could not be performed because the patient rapidly died or
left the hospital against medical advice.7 In the validation popu-
lation, we considered only patients with objectively conﬁrmed PE,
deﬁned by a positive spiral computerized tomography or pulmonary
angiography, a high-probability ventilation/perfusion lung scan,
or proximal deep vein thrombosis documented by compression
ultrasonography.
Baseline demographic (age and sex) and clinical information
(cancer, heart failure, chronic lung disease, pulse, blood pressure,
respiratory rate, temperature, and arterial oxygen saturation
measured by pulse oximetry) and whether patients received throm-
bolysis were prospectively collected by emergency department
physicians and recorded on a standardized data collection instru-
ment.7 Using the baseline data for the prognostic variables in the
prognostic model, we calculated a risk score and risk class for
each patient in the validation population. Because mental status
was not recorded, we assumed mental status to be normal in all
patients in the validation cohort. Missing values for all prognostic
variables were assumed to be normal, a strategy used in the
original derivation of the model and in the development of the
Pneumonia Severity Index, a widely used risk stratiﬁcation tool for
community-acquired pneumonia.5,17
Our primary outcome measure was all-cause mortality 90 days
after presentation for PE. We assessed mortality using patient or
proxy interviews, interview of the patient’s primary care physician,
and/or hospital chart review. Interviews were performed through
telephone and administered by local study coordinators. Two inves-
tigators adjudicated all deaths as deﬁnite, fatal PE and possible,
fatal PE (e.g. sudden death without any obvious cause) or death
from other causes. Our secondary outcomes were objectively con-
ﬁrmed non-fatal VTE (PE or deep vein thrombosis) and non-fatal
major bleeding, deﬁned as any bleeding resulting in disability, hos-
pitalization, or blood transfusion.7 For this project, we excluded all
patients who refused follow-up or who were lost during follow-up.
Methods of analysis
We compared baseline patient’s characteristics between the vali-
dation and the original derivation samples5 using x2 statistics for
categorical variables. To assess the performance of our prognostic
model, we compared the proportions of patients per risk class and
mortality rates within each risk class between the validation and
the original derivation samples.5 To assess the model’s discrimina-
tory power to predict mortality, we compared the area under the
receiver operating characteristic (ROC) curve between the vali-
dation and the original derivation samples.5,18 For all analyses, a
two-tailed P-value of less than 0.05 was used to deﬁne statistical
signiﬁcance. To assess the accuracy of our model to predict mor-
tality, we also compared sensitivity, speciﬁcity, and positive and
negative predictive values and likelihood ratios for low (Risk
Classes I and II) vs. higher risk patients (Risk Classes III–V)
between derivation and validation samples.
Results
Of 1529 patients included in the study, 393 had objectively
conﬁrmed PE, deﬁned by a positive spiral computerized
tomography or pulmonary angiography, a high-probability
ventilation/perfusion lung scan, or proximal deep vein
thrombosis documented by compression ultrasonography.
Of these, we excluded 26 (6.6%) who refused to give
informed consent or who were lost to follow-up, establishing
a validation sample of 367 patients. Excluded patients had
the same demographic and clinical characteristics as
Table 1 Points assigned to prognostic variables in the prognostic
model
Prognostic variables Points
assigned
Demographics
Age (years) Age
Male sex þ10
Comorbid conditions
Cancer þ30
Heart failure þ10
Chronic lung disease þ10
Clinical ﬁndings
Pulse 110 per minute þ20
Systolic blood pressure ,100 mmHg þ30
Respiratory rate 30 per minute þ20
Temperature, 368C þ20
Altered mental statusa þ60
Arterial oxygen saturation ,90%b þ20
A total point score for a given patient is obtained by summing the
patient’s age in years and the points for each applicable prognostic vari-
able. The ﬁve following risk classes are deﬁned based on patients’ total
point score: Class I, very low risk (,65 points); Class II, low risk (66–85
points); Class III, intermediate risk (86–105 points); Class IV, high risk
(106–125 points); and Class V, very high risk (.125 points).
aAltered mental status was deﬁned as disorientation, lethargy, stupor,
or coma.
bArterial oxygen saturation was deﬁned with and without the adminis-
tration of supplemental oxygen.
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enrolled patients. Overall, 23.1% of excluded patients were
classiﬁed in Risk Classes I and II, 11.5% in Class III, 30.8% in
Class IV, and 11.5% in Class V.
Baseline characteristics and outcomes in the
derivation and validation samples
Although patients in the validation sample were older, they
were less likely to have cancer, chronic lung disease,
hypothermia, systolic hypotension, and an altered mental
status when compared with patients in the derivation
sample (Table 2). The higher frequency of hypoxaemia in
the validation sample probably reﬂects the measurement
of arterial oxygenation without supplemental oxygen in
the validation sample. Thrombolysis rates varied from 2.0
to 8.9% and did not differ across risk classes (P ¼ 0.32).
Despite a longer duration of follow-up in the validation
sample (30 vs. 90 days), mortality was lower in the vali-
dation sample (6.3%) than in the derivation sample (9.2%).
Of the 23 patients in the validation sample who died, 11
(47.8%) died from deﬁnite or possible PE, two (8.7%) from
intracranial haemorrhage, and 10 (43.5%) from other
causes. Overall, 15 (65.2%) patients in this sample died
during the ﬁrst 30 days following diagnosis. Only one
patient (0.3%) had non-fatal recurrent VTE and nine (2.5%)
developed non-fatal major bleeding in the validation
sample.
Comparison of the prognostic model in the
derivation and validation samples
The prognostic model classiﬁed a larger proportion of
patients into Risk Classes II and III and a smaller proportion
into Risk Class V in the validation sample than that in the
derivation sample (Table 3). Because age is the most
powerful predictor of adverse outcomes in the model,
almost no patients aged 65 were classiﬁed into Risk Class
I (,0.5%) in both samples, whereas only few patients
under 65 years were classiﬁed into Risk Class V in the deri-
vation (7.7%) and validation samples (2.7%). All ﬁve risk-
class-speciﬁc mortality rates were similar in the derivation
and validation samples and ranged from 0–1.1% in Class I
to 24.4–24.5% in Class V (Table 3). The discriminatory
power of the model, expressed as the area under the ROC
curve, was larger in the validation sample (0.87 vs. 0.78,
P ¼ 0.01) (Figure 1).
In the validation sample, no patients in Risk Classes I, II,
III, and V had non-fatal recurrent VTE during follow-up;
only one patient (1.6%) in Risk Class IV developed deep
vein thrombosis. No patients in Classes I and II, six (6.3%)
in Class III, two (3.2%) in Class IV, and one (2.2%) in Class V
had non-fatal major bleeding during follow-up.
When dichotomized as low risk (Risk Classes I and II) vs.
higher risk (Risk Classes III–V), the model had a negative pre-
dictive value of 98–99% and a negative likelihood ratio of
0.09–0.2 for predicting mortality (Table 4). Because this cut-
point was speciﬁcally chosen to identify low-risk patients
with PE, the positive predictive values (11–14%) and the
positive likelihood ratios (1.6–1.8) for predicting mortality
were low.
Discussion
Our ﬁndings validate a previously developed prognostic
model for patients with PE and conﬁrm its geographic trans-
portability to an independent patient population over a
longer follow-up period.5 Our model accurately identiﬁes
patients with PE who are at low risk of fatal and non-fatal
medical outcomes: none of the patients in Risk Class I in
Table 2 Comparison of baseline characteristics in the derivation and validation samples
Characteristicsa Derivation sample
[n ¼ 10 354(%)]
Validation sample
[n ¼ 367(%)]
P-value
Demographics
Age .65 years 52.8 68.7 ,0.001
Male sex 39.6 38.4 0.66
Comorbid conditions
Cancer 19.9 9.0 ,0.001
Heart failure 16.1 15.5 0.76
Chronic lung disease 18.2 7.9 ,0.001
Clinical ﬁndings
Temperature ,368C 16.7 3.3 ,0.001
Pulse 110 per minute 29.2 25.3 0.11
Systolic blood pressure ,100 mmHg 10.6 3.5 ,0.001
Respiratory rate 30 per minute 14.5 14.2 0.87
Altered mental statusb 6.9 0 ,0.001
Arterial oxygen saturation ,90%c 8.0 18.8 ,0.001
aIn the derivation sample, 1.9% of patients had unknown values for temperature, 1.8% for pulse, 1.4% for systolic blood pressure, 2.0% for respiratory rate,
and 66.5% for arterial oxygen saturation. Comorbid conditions were coded as present vs. unknown. In the validation sample, 0.3% of patients had unknown
values for heart failure, chronic lung disease, for pulse, 17.7% for respiratory rate, 3.3% for systolic blood pressure, 6.3% for temperature, and 4.9% for arter-
ial oxygen saturation. For calculating the frequency of baseline patient’s characteristics, unknown values were assumed to be normal and were included in
the denominator in both samples.
bAltered mental status was deﬁned as disorientation, lethargy, stupor, or coma. In the validation sample, information about mental status was not explicitly
recorded and was assumed to be normal in all patients.
cArterial oxygen saturation was measured with or without supplemental oxygen in the derivation sample and was measured without supplemental oxygen in
the validation sample.
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the validation sample died, had non-fatal recurrent VTE, or
major bleeding within 90 days of the initial PE. Among
patients in Risk Class II, only 1% of patients died and no
patients had recurrent VTE or major bleeding. The negative
predictive value for predicting mortality among low-risk
patients (Risk Classes I and II) varied from 98 to 99%.
There is growing evidence that many patients with non-
massive PE can be safely discharged early or treated entirely
as outpatients using low-molecular-weight heparin.19–21 The
British Thoracic Society recommends outpatient treatment
of clinically stable patients with non-massive PE.22
However, outpatient treatment of such patients is not
widely accepted, because eligibility criteria of prior studies
examining outpatient treatment of PE were relatively unspe-
ciﬁc19–21 and explicit criteria to identify low-risk patients
with PE were not available. Our model, which is entirely
based on simple and objective parameters, could help phys-
icians identify low-risk patients with PE (Risk Classes I and
II) who could be safely treated in the outpatient setting
with low-molecular-weight heparin or if hospitalized, they
are the candidates for early hospital discharge. A recent
cost-effectiveness analysis demonstrated that outpatient
treatment or early discharge of only a small proportion of
patients with PE is likely to result in substantial cost-
savings.23 However, before low-risk patients with PE based
on our model can be treated as outpatients, the safety and
clinical usefulness of this approachmust be tested in a clinical
trial. In addition, aspects of model reliability, for example
interobserver agreement for classifying patients as low vs.
higher risk, should be assessed in a future study. It is also
important to note that our rule is intended to supplement,
not to replace clinical judgement. The initial site of treat-
ment decision for patients with PE must also consider psycho-
social contraindications to outpatient care (e.g. lack of
treatment adherence). Likewise, physicians would be unli-
kely to discharge a previously healthy 40-year-old woman
who has severe hypoxaemia and no additional pertinent
prognostic factors, even if she was classiﬁed as very low risk
(Class I) by the rule.
Whether patients in Risk Class V who have a short-term
mortality of .20% may potentially beneﬁt from more inten-
sive forms of care and surveillance (e.g. in an intensive care
unit setting) remains to be shown.
The original model was derived from a retrospective
cohort of 10 354 inpatients with PE from 186 Pennsylvania
hospitals and internally validated in another 5177 inpatients
with PE from the same sites.5 The model also performed
well in a small external validation sample of 221 patients
prospectively identiﬁed with PE from three Swiss and
French emergency departments.5 Thirty-day mortality
ranged 0–1.6% for patients in Risk Class I, 1.7–3.5% in
Class II, 3.2–7.1% in Class III, 4.0–11.4% in Class IV, and
10.0–24.5% in Class V in these three samples.5 Patients in
Risk Classes I and II had also a low rate of non-fatal
cardiogenic shock, cardiorespiratory arrest, recurrent
VTE, and major bleeding.5 Overall, the accuracy and the
generalizability of the model are now supported by its
derivation and validation in four patient cohorts, comprising
16 119 patients from 305 teaching and non-teaching
hospitals in four countries (USA, France, Switzerland, and
Table 3 Comparison of risk-class distribution and risk-class-speciﬁc mortality in the derivation and validation samples
Per cent (95% conﬁdence Interval) P-value
Derivation sample
(n ¼ 10 354)
Validation sample
(n ¼ 367)
Risk-class distribution
Class I 19.4 (18.7–20.2) 18.0 (14.2–22.3) 0.49
Class II 21.5 (20.7–22.3) 26.7 (22.2–31.5) 0.02
Class III 21.7 (20.9–22.5) 26.2 (21.7–31.0) 0.04
Class IV 16.4 (15.7–17.1) 16.9 (13.2–21.1) 0.79
Class V 21.0 (20.3–21.8) 12.3 (9.1–16.1) ,0.001
Mortality by risk class
Class I 1.1 (0.7–1.7) 0 (0–5.4) 0.64
Class II 3.1 (2.5–4.0) 1.0 (0–5.6) 0.37
Class III 6.5 (5.5–7.6) 3.1 (0.6–8.9) 0.21
Class IV 10.4 (9.0–11.9) 12.9 (5.7–23.9) 0.53
Class V 24.5 (22.7–26.4) 24.4 (12.9–39.5) 0.99
Figure 1 ROC curves for mortality in the derivation and validation samples.
The areas under the ROC curves were 0.78 [95% conﬁdence interval (CI):
0.77–0.80] in the derivation sample and 0.87 (95% CI: 0.80–0.94) in the vali-
dation sample (P ¼ 0.01).
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Belgium) in North America and Western Europe. Patients in
these cohorts had a broad spectrum of disease severity,
ranging from non-massive PE to PE with cardiorespiratory
arrest, and were followed-up to 90 days after the initial
diagnosis.
Our work has potential limitations. First, our validation
sample may not reﬂect the full prognostic spectrum of
patients with PE, because patients had fewer comorbid dis-
eases and fewer signs of physiological instability than
patients in the derivation sample. However, no patient
died in Risk Class I and only 1% of patients died in Risk
Class II, on the basis of our model. Secondly, information
about mental status was not explicitly recorded in the
study used to validate our model.7 Although it is very unli-
kely that more than a few patients had an altered mental
status, we cannot exclude the possibility that disease sever-
ity may have been underestimated in these patients.
Thirdly, 6.6% of patients with PE had to be excluded from
our analyses, because follow-up information was not avail-
able. However, baseline characteristics of excluded and
enrolled patients were not different, making a selection
bias unlikely. Finally, we could not estimate the potential
impact of treatments (e.g. quality of oral anticoagulation
during follow-up) on patient outcomes, because this infor-
mation was not documented in our databases.
In conclusion, we successfully validated our clinical
prognostic model in an independent patient sample with
PE over a more extended duration of follow-up. Although
this model reliably identiﬁes patients at low risk of
mortality and non-fatal adverse outcomes, a clinical trial
is required to assess whether outpatient treatment or
abbreviated inpatient treatment of patients in Risk Classes
I and II is as safe and effective as traditional inpatient
treatment.
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